- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02634567
Attention/Working Memory Rehabilitation in Multiple Sclerosis: A Pilot Project Using Cogmed Working Memory Training
August 12, 2019 updated by: Sarah Morrow, London Health Sciences Centre
Patients diagnosed with any type of multiple sclerosis (MS) who show objective evidence of attention problems will be randomized to standard medical care (treatment as usual) or attention training, which will be completed at their home using a commercially available attention training task (Cogmed Working Memory Training - CWMT) for 5 weeks.
Patients will undergo cognitive testing before and after intervention and at 6 months follow up.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
MS patients who meet the inclusion criteria of the study showing deficits on at least 2 of 3 attention/working measures who will then be randomized to either a treatment group (cognitive rehabilitation training) or a control group (standard clinical care).
Patients must show mild to moderate-severe impairment on 2 out of 3 test measures of processing speed and sustained attention to be included in the study.
Participants will undergo cognitive testing (Minimal Assessment of Cognitive Function in MS [MACFIMS] performed at Dr. Morrow's cognitive clinic at Parkwood Hospital) at pre- and post-treatment, and also at 6-months follow-up.
Participants will also fill out non-cognitive measures in the form of questionnaires regarding quality of life (QoL), self-efficacy, stress, and copying strategies at both pre and post treatment.
In addition, the intervention group will undergo attention training using CWMT for 5 days per week (30-45 minutes daily) for 5 weeks.
They will complete this training by themselves in their home.
The assigned Cogmed coach will set up the Cogmed program for the duration of the trail on the training group participant's computers.
The study will not be able to continue to pay for the Cogmed program after the 5 week training sessions.
Participants are welcome to purchase the software themselves after the entire study has ended if they would like at: http://www.cogmed.com/.
The CWMT (Cogmed) method consists of 25 training sessions done online.
Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week.
The Cogmed program uses an adaptive training approach in which the difficulty level of the training is adjusted in real time (trial by trial basis) based on the trainee's performance.
Each session consists of a selection of various tasks that target the different aspects of attention/working memory.
Specifically, each session will involve training on visuospatial working memory tasks (e.g., remembering the position of objects in a 4 x 4 Grid) as well as verbal working memory tasks (e.g., remembering phonemes, letters, or digits).
Given that adults will be involved in this study, Cogmed QM will be used, a version of the CWMT program adapted for adults.
Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
Additional calls will be made if the Cogmed coaches see the participant is not completing their online training.
Each participant will be assigned a Cogmed qualified coach who is responsible for providing structure, motivation, and feedback on training progress in order to optimize training gains.
Before Cogmed training begins, each participant in the training group will be visited once by their respective Cogmed coach who will ensure that participants' daily Cogmed sessions will be conducted in a space in their home that is conducive to attention training (e.g., little clutter, private area of the home) and ensure consistency between participants.
During training, each participant's performance will be tracked online and will be reviewed by the participant and his/her coach in weekly telephone meetings throughout the five week period.
The participant's performance will be tracked online on the Cogmed platform.
The Cogmed coaches set up the program for the participants and assign them a username.
The Cogmed coaches can track the individual's performance and see who has completed the training based on their username.
No Internet Protocol (IP) information will be collected.
At the end of training, the coach will summarize the training by telephone with the participant.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Gender Both: both female and male participants are being studied
Age Limits Minimum Age: 18 years Maximum Age: 64 years
Accepts Healthy Volunteers? No
Eligibility Criteria
Inclusion Criteria:
- Males/Females, Ages 18-64, with any type of MS
- Lower to moderate physical disability
- Demonstrated impaired attention/working memory on 2 of 3 measures (Patients with a z-score lower than -1.5 on at least 2 of the 3 measures will be characterized as showing attention/working memory deficits)
- Patients must have a Mac or personal computer (PC) computer at home with access to the internet
Exclusion Criteria:
- Clinical relapse/steroid treatment 1 month prior to study entry
- Physical disability that prevents completion of study measures or training
- History of severe mental illness or daily marijuana use
- Those who do not meet the inclusion criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Treatment as Usual
This group will not any training with the Cogmed training program.
|
|
Experimental: Training Group
This group will receive intervention with the Cogmed training program and coach over a period of 5 weeks.
|
The CWMT (Cogmed) method consists of 25 training sessions done online.
Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week.
Each session consists of a selection of various tasks that target the different aspects of attention/working memory.
Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Paced Auditory Serial Addition Test
Time Frame: 7 months
|
Cognitive test; Change pre- to post-test between groups
|
7 months
|
Symbol Digit Modalities Test
Time Frame: 7 months
|
Cognitive test; Change pre- to post-test between groups
|
7 months
|
Stroop colour word test
Time Frame: 7 months
|
Cognitive test; Change pre- to post-test between groups
|
7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Judgement of Line Orientation
Time Frame: 7 months
|
Cognitive test; Change pre- to post-test between groups
|
7 months
|
Controlled Oral Word Association Test
Time Frame: 7 months
|
Cognitive test; Change pre- to post-test between groups
|
7 months
|
California Verbal Learning Test
Time Frame: 7 months
|
Cognitive test; Change pre- to post-test between groups
|
7 months
|
Brief Visual Memory Test
Time Frame: 7 months
|
Cognitive test; Change pre- to post-test between groups
|
7 months
|
Delis-Kaplan Executive Function System Sorting Test
Time Frame: 7 months
|
Cognitive test; Change pre- to post-test between groups
|
7 months
|
Beck Depression Inventory - Fast Screen
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups
|
7 months
|
Hospital Anxiety and Depression Scale
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups
|
7 months
|
Fatigue Severity Scale
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups
|
7 months
|
Short Form Health Survey
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups
|
7 months
|
Dysexecutive Questionnaire
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups in terms of the amount of self-reported issues with executive functions.
|
7 months
|
Cognitive Failures Questionnaire
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups in terms of the amount of self-reported cognitive issues
|
7 months
|
BRIEF Cope
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups
|
7 months
|
Social Stress and Support Interview
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups
|
7 months
|
Multiple Sclerosis Neuropsychological Screening Questionnaire
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups
|
7 months
|
Perceived Deficits Questionnaire
Time Frame: 7 months
|
Non-cognitive Questionnaire; Change pre- to post-test between groups
|
7 months
|
Visual Spatial Span Board Assessment
Time Frame: 7 months
|
Cognitive Test; Change pre- to post-test between groups in the amount of correct sequencing of repeated taping blocks in forward or reverse order from sequence presented by the examiner.
|
7 months
|
Digit Span
Time Frame: 7 months
|
Cognitive Test; Change pre- to post-test between groups in terms of digit sequence memorized and repeated.
A span of 3-9 digits will be repeated forwards and backwards after presentation from the examiner.
|
7 months
|
Arithmetic
Time Frame: 7 months
|
Cognitive Test; Change pre- to post-test between groups, elementary math presented and solved without a pencil and paper.
|
7 months
|
Letter-Number Sequencing
Time Frame: 7 months
|
Cognitive Test; Change pre- to post-test between groups, presented with a combination of letters and numbers; must repeat numbers in ascending order and letters in alphabetical order to examiner.
|
7 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sarah A Morrow, MD, MS, FRCPC (Neurology), London Health Sciences Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2016
Primary Completion (Actual)
November 1, 2018
Study Completion (Actual)
December 1, 2018
Study Registration Dates
First Submitted
December 11, 2015
First Submitted That Met QC Criteria
December 15, 2015
First Posted (Estimate)
December 18, 2015
Study Record Updates
Last Update Posted (Actual)
August 13, 2019
Last Update Submitted That Met QC Criteria
August 12, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 107343
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Cogmed Working Memory Training (CWMT)
-
Radboud University Medical CenterNetherlands Organisation for Scientific ResearchCompletedAttention Deficit Disorder With HyperactivityNetherlands
-
Norwegian University of Science and TechnologyCompletedInfant, Very Low Birth WeightNorway
-
Indiana UniversityCompletedBilateral Hearing LossUnited States
-
University of California, DavisCompleted
-
Boston Children's HospitalThrasher Research Fund; The Children's Heart FoundationCompletedExecutive Function | Congenital Heart Disease | Neurodevelopment | Working Memory Training | Infant Open-heart SurgeryUnited States
-
Boston Children's HospitalUnited States Department of DefenseCompletedChildren | Neurodevelopmental Disorders | Executive Function | Working Memory | Congenital Heart Defect | Infant Open Heart SurgeryUnited States
-
Memorial Sloan Kettering Cancer CenterMARTELL FOUNDATIONActive, not recruiting
-
Helse Stavanger HFCompletedCerebral Palsy | Working Memory TrainingNorway
-
Sorlandet Hospital HFHelse Sor-OstUnknown
-
University of TorontoUnknown